We used a monoclonal antibody and fluorescence immunocytochemistry to localize the product of the bd-2 gene in two cultured human carcinoma cell lines, KB and OVCAR-3.
Introduction
Apoptosis (programmed cell death) is a physiological mechanism that leads to the death of normal cells during embryonic development or as part of cell turnover and dlfferentiation in adult tissues (47) . Apoptosis differs from random cell necrosis in several biochemical and morphological features, not the least of which is that the initiation of the apoptotic pathway is carefully regulated by genetic events (12, 13, 22, 27, 47, 48) . However, despite the diversity of initiating factors in a variety of different cell types, the final biochemical and morphological events of the apoptotic pathway may be common in different systems. It has also recently become apparent that apoptosis may be part of the response of human tumor cells to treatment with many different chemotherapeutic agents or radiation (2,3,47). One hallmark of the apoptotic process is the occurrence of specific fragmentation of cell DNA at intemucleosomal sites, generating a characteristic "ladder" of integer size multiples of DNA fragments of -200 base pairs as detected by gel elec- to taxol, bd-2 remains associated with condensed chromosomes but is lost after >2 days at approximately the same time as the appearance of apoptotic features in these cells. Western blotting indicates that the only extractable protein reactive with this monoclonal antibody under these conditions is a -28 KD form of bd-2. These results suggest a model for the role of bd-2 in protection from apoptosis and a potentially common mechanism by which the final step of apoptosis might be mediated. (JIlistochem Cytochem trophoresis (1, 8) . The character and location of the endonuclease responsible for this specific fragmentation is the subject of active investigation, and preliminary findings indicate that it may be a cytoplasmic rather than a nuclear protein (21, 32) .
Apoptosis can be subdivided into two general categories, one form showing rapid initiation of apoptotic events in cells arrested in the G1 phase of the cell cycle ("primed" apoptosis), and a second form occurring with a longer time course in cells that may require passage through the cell cycle before apoptotic death ("unprimed" apoptosis) (47) . Primed apoptosis, for example, is found in lymphocytes in response to treatment with glucocorticoids (7) or in hormone-dependent cells after the rapid withdrawal of hormone (10, 26, 42) . The apoptotic response of human carcinoma cells to chemotherapy may be more likely to be unprimed (16) ; for example, the treatment of human carcinoma cells with taxol (19, 38) shown in this article leads to apoptotic cell death in some cultured cells only after a period of days. Several authors (2, 9, 11, 24, 40) have pointed out the possible similarities between apoptosis and events that normally occur during progression through the cell cycle, especially at the G 2 / M transition.
Genetic regulation of the general mechanism of apoptosis has recently been firmly established by the observation that cells expressing the bcl-2 oncoprobein are blocked from demonstrating apoptosis (43) (44) (45) . Overexpression of bcl-2, the protein product of the bcl-2 gene, blocks DNA fragmentation and apoptosis in many, although not all, cell types (37, 39) . The bcl-2 gene generates two protein products by altemative splicing, an alpha (26 KD) form containing a hydrophobic C-terminal tail and a beta (22 KD) soluble form (4-6,43,44). The exact mechanism of bcl-2 in preventing apoptosis is still not clear, however. Localization of bcl-2 in cells constitutively overexpressing the alpha form of bcl-2 has shown that this 26 KD protein concentrates on cytoplasmic membranes, including mitochondria and the cytoplasmic face of the nuclear envelope (4, 17, 20, 23, 28, 30, 49) . Cells showing constitutive high levels of bcl-2 expression in normal tissues are restricted to certain specific specialized cell types (18, 33) . In cells showing high-level constitutive expression of bcl-2 there are few if any changes in bcl-2 levels during the cell cycle (35) .
We have employed a commercially available monoclonal antibody (MAb) to human bcl-2 (30, 33) to examine the localization of this oncoprotein in two human carcinoma cell lines, KB cells and OVCAR-3 cells. We have found an unexpected selective localization of bcl-2 duringmitosis in a distribution that suggests a potential model for the role of bcl-2 in inhibition of endonucleosomal DNA cleavage and apoptosis in normal mitosis.
Materials and Methods
Cells. 697 human pre-B leukemia cells and their bd-2-uansfected derivative (29) were the generous gift of Dr. John Reed. KB and OVCAR-3 human carcinoma cells were obtained from the American Type Culture Collection (Rockville, MD) and were propagated in RPMI-1640 medium with 10% fetal calf serum, penicillin, and streptomycin.
Antibodies and Other Reagents. Mouse MAb anti-bcl-2 (#124) was obtained from Dako (Santa Barbara, CA) and has been previously described (30.33) . Affinity-purified goat anti-mouse IgG conjugated to rhodamine was obtained from Jackson ImmunoResearch (West Grove, PA). Tax01 was a gift from Dr. Patricia Pilia (NaPro Biotherapeutics; Boulder, CO). When indicated, cells were treated with taxol by including 0.25-1 pM taxol in their normal culture medium. Concentrations of taxol in this range produced similar results.
Immunofluorescence Procedures. Various fixation protocols were examined for their ability to retain bcl-2 and allow access to nuclear sites. Formaldehyde primary fixation followed by incubation in the continuous presence of saponin (0.1%) as previously described (46) produced good morphological preservation and allowed labeling of cytoplasmically accessible bcl-2. However, since saponin treatment does not allow access through the nuclear envelope (14), we tested post-fixation treatment with Triton X-100 and acetone, as well as primary fixation with acetone alone. All of these procedures produced similarly acceptable results, but for simplicity the experiments shown here employed primary fixation in acetone only. Plastic dishes (35 mm) with attached cells were washed free of medium and fixed in 80% acetone/20% water at room temperature (RT) for 10 min. For suspended cells, dishes were pre-coated with poly-Llysine (1 mg/ml, 23'C, 5 min) and washed in PBS, followed by centrifugation of cells suspended in protein-free medium onto the coated dish surface. After washing in PBS, the cells were then incubated in a mixture of 4 mglm normal goat globulin, 0.1% saponin, and PBS (NGG-sap-PBS), and this diluent was used to prepare all of the subsequent antibody incubations. Cells were then exposed to 10 pg/ml mouse MAb #I24 in NGG-sap-PBS for 30 min, followed by washing and further incubation in 25 p g / d rhodamine-conjugated affinity-purified goat anti-mouse IgG for 30 min, all steps occurring at RT. The cells were then washed in PBS, post-fiued in 3.7% formaldehyde in PBS for 10 min. and mounted in glycerol under a #I circular coverslip. The cells in dishes were examined with a Zeiss Axioplan fluorescence microscope equipped with rhodamine filters and photographed with Kodak Tri-X film developed in Diafine. Controls included a non-reactive mouse MAb or omission of the antibody in the first step, both ofwhich were negative.
Quantitation of Nudeat DNA Content. Cells labeled with anti-bcl-2 were incubated after the post-fixation step with 1 pg/ml DAPI (4',6diamidino-2-phenylindole) (Molecular Probes; Eugene, OR) in PBS for 10 min at RT. After washing in PBS and mounting in glycerol, the cells were examined with a Neofluar ( x 100, NA 1.3) objective with sequential rhodamine channel and w channel examination. The field diaphragm was adjusted to encompass one nucleus (m30 pm diameter). The fluorescence light output of each nucleus was then measured using the exposure meter (MC 100 camera system) digital reading of exposure times at an ASA setting of 400. The reciprocal of this exposure time was then used as an index of fluorescence intensity. Values were standardized vs known daughter cell figures (2n amount of DNA) and mitotic metaphase figures (4n amount of DNA). Cells with nuclei positive or negative for bcl-2 localization were selected and categorized on the rhodamine channel and then examined for DNA content using the uv excitation channel for DAPI fluorescence.
The rhodamine fluorescence signal had no effect on the intensity of the DAPI signal, since cells not incubated with DAPI showed no signal on the w channel.
Western Blotting of bcl-2 in Cell Extracts. Cell extracts of taxol-treated KB and untreated 697 cells were prepared by scraping washed cells, freeting them in liquid nitrogen, then extracting with SDS buffer and boiling. This was followed by gel electrophoresis using a 12% polyacrylamide gel and electtoelution onto nitrocellulose paper. These blots were then incubated with MAb #124 followed by detection as previously described (3).
DNA Exuaction and Analysis. DNA was isolated from OVCAR-3 cells that had been either untreated or taxol-treated for 2 days (0.25 pM taxol). Purification was accomplished with a "Magic Miniprep" kit (Promega; Madison, WI). The DNA pellet from one T-75 flask of cells was re-suspended in 100 pl of buffer, and a 10-pl aliquot was loaded in one lane of a 0.8% agarose gel, followed by electrophoresis. The resultant bands were visualized by ethidium bromide staining.
Results

Immunocytochemical Localization in LeuRemic Cell. Overexpressing bcl-2
We examined the distribution of bcl-2 with a commercially available MAb reactive with an epitope shared by both the alpha and beta forms of bcl-2 (30, 33) in cultured human pre-B leukemia cells (29) expressing high levels of bcl-2. These cells (697 cells) showed the same membrane-associated cytoplasmic pattern previously described in other cells by Monaghan et al. (30) (Figure 1A') . A similar experiment in 697 cells transfected with the human bcl-2 gene (697lbcl-2) (29), which express even higher levels of bcl-2 protein, showed an essentially identical pattern with higher intensity (Figure IB) . Therefore, the locdization seen with this MAb and our immunofluorescence methods agrees with the previously published patterns seen in such cells.
Immunocytochemical Localization of bcl-2 in Carcinoma Cells
We next examined the localization of bcl-2 in the cultured human carcinoma cell lines KB and OVCAR-3, cells not known to express bcl-2 protein in significant amounts. Interphase cells in both of these cultures showed no detectable expression of bcl-2 ( Figures  2A and 2H ). However, occasional cells in the culture showed localization which, when examined more closely, showed a highly specific mitosis-related pattern. Both cell types showed that cells in prophase ( Figures 2C and 2J ) had localization concentrated around condensed chromosomes, a pattern also found in metaphase (Figures 2D and 2K) and anaphase ( Figures 2E and 2L ). In some anaphase cells the intensity of label was less than in metaphase. Cells in telophase were completely negative ( Figures 2F and 2M ). These results are diagrammatically summarized in Figure 3 .
Cell Cycle Position of Nucleated Cells Expressing bcl-2
Certain rare nucleated cells showed a bright, apparently diffuse nuclear localization of bcl-2 ( Figures 2B and 21 ). Many of these nucleated cells, on closer examination, showed some condensation of chromatin by phase-contrast microscopy. We therefore examined the DNA content per cell using simultaneous DAPI labeling to label DNA along with rhodamine immunofluorescence labeling of bcl-2. Figure 4 shows the results of these quantitative measurements and shows that nucleated cells with bcl-2 labeling had postsynthetic levels of DNA, demonstrating that they were all in the G2 phase of the cell cycle. Thus, bcl-2 expression appeared in G2 nuclei, followed by aggregation around condensed chromosomes in prophase, metaphase, and anaphase, with disappearance before telophase.
Bcl-2 Localization in Taxol-treated Carcinoma Cells
Treatment ofcells with taxol leads to mitotic arrest, with persistent accumulation of arrested cells with continued incubation (19, 25, 38) . Apoptotic features of these KB and OVCAR-3 cells were not prominent until the Day 2 of taxol incubation. When cells were treated with taxol for 1 day, approximately half of the cells were mitotically arrested. Immunofluorescence examination of these arrested cells showed the same concentration of bcl-2 around chromosomes seen during normal mitosis in untreated cells ( Figures TA' and 5B) .
When the taxol treatment was continued for 2 days, apoptotic figures could be found which, when examined by immunofluorescence, showed loss of bcl-2 localization ( Figures 5C' and 5D' ).
Biochemical IdentzFcation of the Antigen Reactive with Anti-bcl-2
To examine the biochemical nature of the immunofluorescence patterns seen, KB cells treated with taxol for 1 day were extracted and the extracts were subjected to SDS-PAGE and Western blotting with MAb anti-bcl-2 (#124). Figure 6 shows that the only detectable band reactive with anti-bcl-2 in the taxol-treated cells was a -28 KD band, a band that ran at a slightly higher molecular weight compared with the -26 KD alpha form of bcl-2 seen in 697 cells ( Figure 6 ).
Analysis of D N A Fragmentation
OVCAR-3 cells treated with taxol for 2 days were extracted and the DNA from these cells was analyzed with agarose gel electrophoresis. Figure 7 shows that cells treated with taxol, similar to those shown in Figure SD , exhibit extensive DNA fragmentation in the internucleosomal -200 BP pattern expected for cells in apoptosis.
Discussion
Taxol and bcl-2
Taxol has shown clinical efficacy in the treatment of a variety of human tumors, and it has been recently demonstrated that taxol (19, 38) can induce apoptotic cell death in human leukemic cells (3). The possibility that apoptosis might be part of the success of taxol in treating human tumors prompted us to examine this process in other cell types. In this article we have shown that taxol causes apoptotic changes in human carcinoma cells when taxol incubations are continued for several days. Bcl-2 expression has been shown to inhibit apoptosis in a variety of cell types. We therefore exam- ined the localization of bcl-2 in human carcinoma cells because we were interested in the role it might play in the apoptosis induced by taxol in such cells, cells that might be more typical of those found in solid human tumors.
Previous Findings of bcl-2 Location in Cells
Prior data conceming bcl-2 localization in cells utilized cell types, such as leukemic cells, that constitutively express very high levels of bcl-2, levels that do not vary significantly during the cell cycle (36) . Such cells show localization in a cytoplasmic membraneassociated pattern (30) , similar to that we have confirmed in this article in examining 697 and 697/bcl-2 cells. Examination of some other cell types had suggested very little bcl-2 expression when measured quantitatively (6,36). Bcl-2 expression in several cell types has been associated with a block in the apoptotic process induced by different initiating causes (17, 28, 29) , suggesting that bcl-2 might affect a common final pathway by which apoptosis occurs. One of the hallmark features of apoptosis is the fragmentation of cell DNA at intemucleosomal sites (8, 21, 32, 48) . How this fragmentation occurs and the location of the endonuclease that might cause it are not clear. The target of this nuclease would be nuclear DNA, yet bcl-2 localization has been documented only in a cytoplasmic location (30) . Therefore, the role by which bcl-2 might affect DNA fragmentation directly has been difficulty to understand. A mitosis-specific bcl-2 distribution has not been previously reported. Mitosis is an infrequent event, even in rapidly growing cultured cells, representing less than 1% of the total cell population at any given moment. Mass examination of whole cultures or cell populations would make detection of events that were mitosisspecific difficult. Immunocytochemistry, on the other hand, allows the dissection of such infrequent events by examination of individual cells in a large population. Mitosis-specific events in intact tissues (18, 49) , where most cells are not cycling, or in suspension cultures (30), where mitotic cells would be difficult to identify, would be very rare.
Bcl-2 in Mitosis and a Hypothesis Concerning Its Action
The finding in this study of a mitosis-specific localization of bcl-2 is unexpected and suggests a possible physiological role for bcl-2 in normal cellular events. It also suggests a mechanism by which these physiological properties of bcl-2 might affect the apoptotic process by directly affecting the nuclease fragmentation of cell DNA. Many elements of this hypothesis are not new and have been suggested as possibilities by previous authors (9, 11, 24, 40) , but the role that bcl-2 might play in the specifics of this mechanism, as evidenced by the data in our study, adds a different view of the steps that might operate in this process. This hypothesis is diagrammatically summarized in Figure 8 .
The specific expression of bcl-2 at the beginning of mitosis, before the disassembly of the nuclear envelope barrier, and its disappearance in telophase, when the barrier reappears, suggest that bcl-2 attached to chromosomes serves a specific function during the time that chromosomes are accessible to the cytoplasm, The most obvious interpretation would be that bcl-2 serves a protective role, preventing nuclease attack at internucleosomal sites. This predicts that either the nuclease is uniquely cytoplasmic or that it is activated when the nuclear envelope barrier is removed. If such a protective mechanism is necessary in mitosis, then it might explain part of the process that could lead to the apoptotic DNA damage that occurs in cells that begin apoptotic events in earlier parts of rhe cell cycle. From the results presented here, bcl-2 is likely to be absent from most interphase carcinoma cells. If anything caused a dissolution of the nuclear envelope barrier in interphase. even transiently, the absence of bcl-2 might allow nuclease cleavage of nuclear DNA by a cytoplasmic nuclease; this would not normally occur in mitosis because of the protective presence of bcl-2. Such an interphase event might be part of the mechanism of primed apoptosis in cells that are in GI or S-phase when the apoptosisinducing event occurs. Overexpression of bcl-2 during the entire A B C p . Figure 7 . Agarose gel electrophoresis of DNA extracted fmm tml-treated OVCAR-3 cells. OVCAR-3 cells were treated with tax01 for 2 days corresponding to the images shown in Figure 5D . DNA extracts of these cells were prepared and subjected to agarose gel electrophoresis and visualized using ethidium bromide. Lane Ashows the absenceof DNA fragmentation in untreated cells, whereas Lane 8 shows the appearance of DNA 'ladders" at -200 BP intervals characteristic of apoptosis. Lane C shows DNA slze standards. Note the 500 BP standard that lies just below the third band from the bottom in Lane E, a band that should correspond to -600 BP in size. High molecular weight DNA is not seen in these gels because the extraction-purification method used selects mainly for low molecular weight DNA.
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cell cycle would be expected to prevent this nuclease activity in a manner similar to its physiological role in mitosis. This nuclearcnvelope barrier leakage could be a consequence of a general cellular signal to enter mitosis. In cells unprepared for mitosis, however, and lacking the bcl-2 localization that occurs in late G2. this mitosis entry signal could lead to unprotected nuclease access to nuclear DNA and subsequent apoptosis. The observation with in situ methods in apoptotic cells that DNA strand breaks first occur at the margins of nuclei supports this concept (15). It has previously been noted that there is a similarity between events that precede mitosis and those that precede apoptosis, suggesting that some forms of apoptosis might be "premature mitosis" (11, 24) . The results presented here suggest that part of that mechanism might be the absence of cell cycle-dependent bcl-2 expression. Although the localization of bcl-2 shown here strongly suggests that it is newly expressed in early prophase and lost at telophase, it is still formally possible that the pattern seen might represent morphological redistribution of pre-existing bcl-2 rather then new synthesis and degradation. In addition, the accessibility of the epitope reactive with this MAb might be altered in a specific way at other parts of the cell cycle. Experiments examining the bcl-2 content of synchronized cell populations biochemically should clarify this question.
Taxol-induced Apoptosis
The mechanism by which taxol could lead to apoptosis is not entirely clear. However, it is noteworthy that apoptotic events in OVCAR-3 cells require at least 1-2 days to appear. During this time these cells are arrested in mitosis due to the prevention of spindle formation by taxol. Normal mitosis is a rapid event that takes less than 1 hr. To prolong mitotic arrest might overcome protective mechanisms in cells that prevent chromosomal damage during the mixing of the nuclear and cytoplasmic compartments. It is possible that bcl-2 plays a role in such protective mechanisms and that prolongation of mitotic arrest eventually leads to bcl-2 degradation, since it cannot be replaced by new protein synthesis. Our finding that apoptotic cells show loss of bcl-2 localization after 2 days in the presence of taxol is consistent with this concept.
Questions Raised &y These Data
The chromosome-specific location of bcl-2 seen only in late G2 or prophase suggests that bcl-2 has a nucleus-targeted and chromo-some-specific property. Whether this targeting is mediated by bcl-2 alone or is the consequence of bcl-2 association with other targeted elements is not known. One such targeted element might be the nuclease itself, which might be complexed with bcl-2, target to internucleosomal DNA, but be inhibited in its action by the presence of bcl-2. If bcl-2 remained associated with chromatin after telophase it might interfere with subsequent transcriptional events. It is noteworthy that cells overexpressing bcl-2 that survive express the membrane-bound form of the protein, bcl-2 alpha (4, 33, 35, 41) . Whether the form we see in mitosis is the alpha or beta form, or some other post-translational modification, is not clear. The molecular weight (-28 m k o f the bcl-2 found in taxol-arrested cells approximates the 26 KD alpha form, which should be membraneassociated because of its hydrophobic C-terminal region. Yet the pattern we see is not that expected for a membrane-associated protein. It is possible that this bcl-2 alpha is modified physiologically by complexing with a nuclear targeting or chromosomal attachment element that might cause it to remain soluble and not associate with membranes. It k also noteworthy that cells possessing relatively higher levels of bcl-2 alpha, such as 697 cells, are not totally inhibited from entering apoptosis until the bcl-2 alpha levels are very high, such as in 697/bcl-2 cells (29) . This suggests that the membrane-bound form might interact with a very large pool of some element, such as a nuclease, to prevent apoptotic DNA damage. Alternatively, the gross overexpression of the alpha form may be necessary to allow a small amount of excess bcl-2 to associated with the actual sites of nuclease inhibition, such as the chromosome sites we have shown in this article. In this regard, experiments in which the alpha or beta forms of bcl-2 have been selectively expressed in cells and examined for effects on apoptosis have suggested that the beta form is not effective in preventing apoptosis (41) . This is in spite of the observation that both forms are oncogenic in animals (34) . However, not only the expression of the protein but its morphological compamnenmlization may be important, and other elements not present in such cells may be necessary for the proper nuclear targeting of the soluble beta form in interphase cells, elements that are normally only expressed in a cell cycle-specific manner in Gz.
Predctions of the Hypothesis
This hypothesis suggests several testable elements. If bcl-2 expression could be prevented or redistributed in mitotic cells, then these cells might enter apoptosis due to the absence of bcl-2 effects alone and show this apoptotic entry only after entry into mitosis. Similarly, preventing cells from entering prophase might prevent the access of a cytoplasmic nuclease to nuclear DNA and prevent apoptosis due to microtubule-targeted drugs such as taxol. In support of this concept, preliminary results have shown that genistein, an inhibitor of tyrosine kinase that arrests leukemic cells in GI, subsequently also prevents taxol-induced apoptosis (K. Bhalla, manuscript in preparation). On the other hand, sequentially treating cells with agents that arrest them first in Gz might lead to bcl-2 degradation before the beginning of mitosis, and a much higher sensitivity to apoptosis after the mitotic arrest produced by agents such as taxol. This might lead to a more rational approach to sequential chemotherapy in the clinical setting. Correspondingly, artificial creation of transient nuclear envelope breakdown in in-terphase cells would be expected to lead to apoptosis without the need for mitotic entry. One might also expect that inhibition of bcl-2 expression in other cells might affect apoptotic entry only if the inhibition occurred in late G2. Experiments designed to test these predictions should help to c l a r~ the relationships suggested in this hypothesis and to delineate the actual role of bcl-2 mitotic expression in apoptosis and other cellular events.
